---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-23-000179"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:22:22.588871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition

## Summary
- Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).
- In-line and new product portfolio revenue grew 8% YoY (7% ex-FX).
- Acquired IPRD and licensing charges reduced GAAP and non-GAAP EPS by $0.03 per share.
- Planned acquisition of Mirati Therapeutics to strengthen oncology pipeline; terms not disclosed.
- Adjusted 2023 GAAP EPS guidance downward; raised midpoint of non-GAAP EPS guidance range.

## SEC filing metadata
- accession: 0000014272-23-000179
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/0000014272-23-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/bmy-20231026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-23-000179
- JSON: https://secwatch.observer/filing/0000014272-23-000179.json
- Plain text: https://secwatch.observer/filing/0000014272-23-000179.txt

## Key facts
- Earnings Releases
  BRISTOL MYERS SQUIBB CO reported the third quarter of 2023 results: revenue $10,966, EPS 0.93.
  - Period: the third quarter of 2023
  - Revenue: $10,966
  - EPS: 0.93
  - Result: reported results
  source text: business development opportunities that benefit patients." 1 Third Quarter $ amounts in millions, except per share amounts 2023 2022 Change Change Excl. F/X** Total Revenues $10,966 $11,218 (2) % (3) % Earnings per share - GAAP* 0.93 0.75 24 % N/A Earnings per share - Non-GAAP* 2.00 1.99 1 % N/A * GAAP and Non-GAAP earnings per share include the net impact of
  evidence_url: https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/0000014272-23-000179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.